| Management team |
|
Hans Rosén, born 1960President Mr. Rosén has served as CEO of Artimplant since 2006. Mr. Rosén has extensive experience from marketing, sales and corporate management in the life science sector. Most recently Mr. Rosén was CEO of Vivolux AB, a drug development company within cancer therapeutics. Former president of the listed company Diffchamb AB and has held leading positions in Neoventa and Chromogenix. Director of Vivolux AB and Ottonova AB. Mr. Rosén holds an MSc in Industrial Engineering and Management from Chalmers University of Technology. Other Assignments:Member of the Board of Vivolux AB and Ottonova AB. Holdings in Artimplant:70 000 Series B stock units including family members holdings. Employee incentive call options 117 056 program 2006/2011, 110 000 program 2007/2012, 112 500 program 2008/2013, 112 500 program 2009/2014. Lars-Johan Cederbrant, born 1971CFO Employed by Artimplant since 2005. Mr. Cederbrant has experience in finance, management, business development and restructuring from international growth companies within the medical technology industry. He has among others been CEO of CardioBridge GmbH, CFO during the restructuring of JOMED N.V. and Management Consultant at Andersen Business Consulting. Mr. Cederbrant studied MSc in International Business Administration at the University of Lund and at Leopold Franzen´s University of Innsbruck. Other Assignments:Advisory board member of Inventive Capital LLP. Holdings in Artimplant:89 000 Series B stock units. Employee incentive call options 49 500 program 2005/2010, 26 223 program 2006/2011, 44 799 program 2007/2012, 40 000 program 2008/2013, 44 000 program 2009/2014. Katrin Gisselfält, born 1969Vice President Product Development, Ph.D. Dr. Gisselfält has been employed by Artimplant since 1995. She is one of the key scientists behind Artelon®. Katrin Gisselfält holds a Ph.D. degree in Polymer Chemistry, Chalmers University of Technology, Gothenburg. The primary field of research has been synthesis, characterization and processing of degradable poly(urethane urea)s and their use as biomaterials. Holdings in Artimplant:15 000 Series B stock units. Employee incentive call options 49 500 program 2005/2010, 26 223 program 2006/2011, 44 799 program 2007/2012, 40 000 program 2008/2013, 44 000 program 2009/2014. Kauko Haapasaari, born 1958
|

